A Study to Evaluate the Safety and Efficacy of FYU-981 in Hyperuricemic Pediatric Patients with or without Gout (Phase III Study) (Extension Study)
Latest Information Update: 17 Oct 2024
Price :
$35 *
At a glance
- Drugs Dotinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Fuji Yakuhin
- 17 Oct 2024 New trial record